Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know
Key Points
These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342.
The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.
Bartolucci retains direct ownership of 67,866 shares valued at $3.35 million based on the August 18 market close.
- 10 stocks we like better than Tempus AI ›
Ryan M. Bartolucci, the chief accounting officer of Tempus AI, Inc. (NASDAQ:TEM), reported a sale of 6,175 shares of Class A Common Stock on August 18, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$306,342 |
| Shares sold (directly held) | 6,175 |
| Post-transaction shares (directly held) | 67,866 |
| Post-transaction value | $3.35 million |
Transaction value based on SEC Form 4 weighted average sale price ($49.61); post-transaction value based on the August 18 market close ($49.36).
Key questions
- What was the primary driver behind this transaction?
The sale was a non-discretionary execution required by the company's equity incentive plan to satisfy minimum statutory tax withholding obligations associated with the vesting of restricted stock units. - How does this impact the insider's direct equity position?
Following this disposition of 6,175 shares, the reporting person maintains direct ownership of 67,866 shares of Class A Common Stock. - What is the insider's total beneficial ownership interest in the firm?
The executive's direct holdings represent an ownership stake of 0.04% of the company as of the August 20 filing date. - Does the transaction provide insight into management's view of current valuation?
As an automatic tax-related transaction rather than a discretionary market order, this activity does not reflect a change in the insider's sentiment regarding the stock price, which was $61.25 as of the August 19 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $61.25 |
| Market Capitalization | $10.7 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop, full-stack healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, advanced analytics, and a comprehensive repository of multimodal data to support precision medicine applications.
- The company generates revenue through its proprietary Tempus platform and Hub clinical application, which provide next-generation sequencing (NGS) tests and diagnostic services to healthcare providers, and is centered on enabling data-driven clinical decision-making.
- Tempus AI serves physicians, healthcare providers, and clinical laboratories as primary customers, targeting the oncology and precision medicine markets where genomic testing and advanced analytics drive improved patient outcomes.
Tempus AI is a healthcare technology company with a market capitalization of $10.7 billion and TTM revenue of $1.4 billion, operating as a leading provider of AI-enabled diagnostic and analytics platforms for precision medicine. The company's integrated platform architecture creates a competitive advantage by combining clinical workflow optimization with proprietary laboratory capabilities and advanced data analytics. With 3,800 employees and headquarters in Chicago, Tempus AI is positioned at the intersection of genomics, artificial intelligence, and clinical diagnostics, though the company is currently in a growth investment phase with negative net income of -$254.4 million TTM.
What this transaction means for investors
Bartolucci's sale is the smallest in a batch of several among Tempus AI executives and landed the same day as other tax withholdings on vested RSUs, transactions that were notably priced the day before the Moderna and Merck trial news sent Tempus stock up 24%, which in a way highlights how non-discretionary this type of move was.
His title puts him closer to a detail in this quarter's results that's easy to skim past. Tempus reported its first GAAP profit in the second quarter, racking up net income of $5.6 million, but that number leaned heavily on non-operating items rather than the core business turning a corner. It included $98.5 million in unrealized gains on marketable securities and $55.6 million in stock compensation and payroll tax expense running the other direction. Strip those out, and the company posted a non-GAAP net loss of $7.7 million for the quarter, which, to be fair, was still a big improvement from a year earlier. Getting that distinction right in the filings is Bartolucci's job, and it's the more useful thing to understand about this quarter than his 6,175 shares that went out the door.
Should you buy stock in Tempus AI right now?
Before you buy stock in Tempus AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,189!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,330,956!*
Now, it’s worth noting Stock Advisor’s total average return is 967% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 22, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.
Recommended Articles
